307 related articles for article (PubMed ID: 32589751)
1. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
Coopmans EC; Korevaar TIM; van Meyel SWF; Daly AF; Chanson P; Brue T; Delemer B; Hána V; Colao A; Carvalho D; Jaffrain-Rea ML; Stalla GK; Fajardo-Montañana C; Beckers A; van der Lely AJ; Petrossians P; Neggers SJCMM
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32589751
[TBL] [Abstract][Full Text] [Related]
2. Normal Insulin-like Growth Factor 1 During Somatostatin Receptor Ligand Treatment Predicts Surgical Cure in Acromegaly.
Losa M; Garbin E; Pedone E; Mortini P
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32609842
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective.
Nista F; Corica G; Castelletti L; Khorrami K; Campana C; Cocchiara F; Zoppoli G; Prior A; Rossi DC; Zona G; Ferone D; Gatto F
Front Endocrinol (Lausanne); 2021; 12():677919. PubMed ID: 34025586
[TBL] [Abstract][Full Text] [Related]
4. Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.
Samson SL; Nachtigall LB; Fleseriu M; Gordon MB; Bolanowski M; Labadzhyan A; Ur E; Molitch M; Ludlam WH; Patou G; Haviv A; Biermasz N; Giustina A; Trainer PJ; Strasburger CJ; Kennedy L; Melmed S
J Clin Endocrinol Metab; 2020 Oct; 105(10):e3785-97. PubMed ID: 32882036
[TBL] [Abstract][Full Text] [Related]
5. Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands.
Wildemberg LE; da Silva Camacho AH; Miranda RL; Elias PCL; de Castro Musolino NR; Nazato D; Jallad R; Huayllas MKP; Mota JIS; Almeida T; Portes E; Ribeiro-Oliveira A; Vilar L; Boguszewski CL; Winter Tavares AB; Nunes-Nogueira VS; Mazzuco TL; Rech CGSL; Marques NV; Chimelli L; Czepielewski M; Bronstein MD; Abucham J; de Castro M; Kasuki L; Gadelha M
J Clin Endocrinol Metab; 2021 Jun; 106(7):2047-2056. PubMed ID: 33686418
[TBL] [Abstract][Full Text] [Related]
6. Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment.
Prencipe N; Bona C; Cuboni D; Parasiliti-Caprino M; Berton AM; Fenoglio LM; Gasco V; Ghigo E; Grottoli S
Pituitary; 2021 Apr; 24(2):242-251. PubMed ID: 33164134
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.
Brzana J; Yedinak CG; Gultekin SH; Delashaw JB; Fleseriu M
Pituitary; 2013 Dec; 16(4):490-8. PubMed ID: 23184260
[TBL] [Abstract][Full Text] [Related]
8. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials.
Alquraini H; Del Pilar Schneider M; Mirakhur B; Barkan A
Pituitary; 2018 Jun; 21(3):283-289. PubMed ID: 29357081
[TBL] [Abstract][Full Text] [Related]
9. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly.
Coopmans EC; Schneiders JJ; El-Sayed N; Erler NS; Hofland LJ; van der Lely AJ; Petrossians P; Potorac J; Muhammad A; Neggers SJCMM
Eur J Endocrinol; 2020 Jun; 182(6):595-605. PubMed ID: 32375119
[TBL] [Abstract][Full Text] [Related]
10. Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.
Samson SL
Neuroendocrinology; 2015; 102(1-2):8-17. PubMed ID: 25792118
[TBL] [Abstract][Full Text] [Related]
11. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
12. High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study.
Giustina A; Mazziotti G; Cannavò S; Castello R; Arnaldi G; Bugari G; Cozzi R; Ferone D; Formenti AM; Gatti E; Grottoli S; Maffei P; Maffezzoni F; Montini M; Terzolo M; Ghigo E
J Clin Endocrinol Metab; 2017 Jul; 102(7):2454-2464. PubMed ID: 28419317
[TBL] [Abstract][Full Text] [Related]
13. GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil.
Manosso KZB; Sampaio CL; Kasuki L; Antunes X; Gadelha MR; Boguszewski CL
Endocrine; 2021 Oct; 74(1):146-154. PubMed ID: 34041695
[TBL] [Abstract][Full Text] [Related]
14. ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly.
Gadelha MR; Gordon MB; Doknic M; Mezősi E; Tóth M; Randeva H; Marmon T; Jochelson T; Luo R; Monahan M; Madan A; Ferrara-Cook C; Struthers RS; Krasner A
J Clin Endocrinol Metab; 2023 Apr; 108(5):e148-e159. PubMed ID: 36353760
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor ligands in the treatment of acromegaly.
Gadelha MR; Wildemberg LE; Bronstein MD; Gatto F; Ferone D
Pituitary; 2017 Feb; 20(1):100-108. PubMed ID: 28176162
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance.
Paragliola RM; Corsello SM; Salvatori R
Pituitary; 2017 Feb; 20(1):109-115. PubMed ID: 27778296
[TBL] [Abstract][Full Text] [Related]
17. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.
Fleseriu M; Dreval A; Bondar I; Vagapova G; Macut D; Pokramovich YG; Molitch ME; Leonova N; Raverot G; Grineva E; Poteshkin YE; Gilgun-Sherki Y; Ludlam WH; Patou G; Haviv A; Gordon MB; Biermasz NR; Melmed S; Strasburger CJ
Lancet Diabetes Endocrinol; 2022 Feb; 10(2):102-111. PubMed ID: 34953531
[TBL] [Abstract][Full Text] [Related]
19. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly.
Gatto F; Feelders RA; van der Pas R; Kros JM; Waaijers M; Sprij-Mooij D; Neggers SJ; van der Lelij AJ; Minuto F; Lamberts SW; de Herder WW; Ferone D; Hofland LJ
J Clin Endocrinol Metab; 2013 Jan; 98(1):E66-71. PubMed ID: 23118420
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain.
Biagetti B; Iglesias P; Villar-Taibo R; Moure MD; Paja M; Araujo-Castro M; Ares J; Álvarez-Escola C; Vicente A; Álvarez Guivernau È; Novoa-Testa I; Guerrero Perez F; Cámara R; Lecumberri B; García Gómez C; Bernabéu I; Manjón L; Gaztambide S; Cordido F; Webb SM; Menéndez-Torre EL; Díez JJ; Simó R; Puig-Domingo M
Front Endocrinol (Lausanne); 2022; 13():984877. PubMed ID: 36187107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
